← Back to home

SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASES

Clinical trials for SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASES explained in plain language.

Never miss a new study

Get alerted when new SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASES trials appear

Sign up with your email to follow new studies for SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for halting autoimmune lung scarring in major trial

Disease control Recruiting now

This study is testing whether a new oral medicine called nerandomilast can slow down lung scarring in people whose autoimmune disease has affected their lungs. It involves 400 adults whose lung function has not improved with standard treatments. Participants will take either the …

Matched conditions: SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASES

Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Mar 30, 2026 14:27 UTC

SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASES

Get alerted when new SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASES trials appear

New hope for halting autoimmune lung scarring in major trial